Dryden Capital’s European Biotech Acquisition Corp. Warrant EBACW Stock Holding History

Dryden Capital’s Portfolio EBACW Stock Details EBACW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-15,000	Closed	-$4.47K	–	39
2022 Q4	$4.47K	Hold	15,000	–	–	0.01%	34
2022 Q3	$0	Hold	15,000	–	–	﹤0.01%	58
2022 Q2	$1K	Hold	15,000	–	–	﹤0.01%	54
2022 Q1	$3K	Hold	15,000	–	–	﹤0.01%	55
2021 Q4	$9K	Buy	+15,000	New	+$9.59K	0.01%	43

Dryden Capital's EBACW Position: Q1 2023 in Review

Dryden Capital sold out of European Biotech Acquisition Corp. Warrant (EBACW) in Q1 2023, closing a stake of 15,000 shares — an estimated $4.47K sold.

Dryden Capital first reported a position in EBACW in Q4 2021 and held it in 5 quarters. The position peaked at $9K in Q4 2021. 0 funds tracked by Wall St. Rank hold EBACW as of Q1 2023.

Dryden Capital reported no remaining European Biotech Acquisition Corp. Warrant position as of Q1 2023 after selling out during the quarter.
Dryden Capital sold 15,000 European Biotech Acquisition Corp. Warrant shares in Q1 2023, an estimated $4.47K.
Dryden Capital first reported a position in European Biotech Acquisition Corp. Warrant in Q4 2021 and held it in 5 quarters.
Dryden Capital's European Biotech Acquisition Corp. Warrant position peaked at $9K in Q4 2021.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Warrant as of Q1 2023.

Based on Dryden Capital's 13F filing for Q1 2023, filed 15 May 2023.